Pentadecanoic Acid (C15:0)

Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Pentadecanoic acid (C15:0) is an odd-chain saturated fatty acid found naturally in dairy fat, some plants, and certain fish. Historically considered nutritionally inert, recent research — much of it from Stephanie Venn-Watson's group (founders of the Fatty15 brand) — has proposed that C15:0 may function as a previously overlooked essential fatty acid with broad cellular health benefits. Published work has shown C15:0 activity across mitochondrial repair, anti-inflammatory signaling, AMPK and PPAR pathway modulation, and antifibrotic effects in cell-based assays. Independent confirmation of essentiality status is still developing and the framework is debated in the lipid science community. Used as a single-compound supplement at modest mg doses; safety data is generally favorable.

Studied Dose 100-200 mg/day (single capsule); taken with food. Most published cellular and observational work supports the low-mg daily dose range; long-term human RCT dose ranging is still emerging.
Active Compound Pentadecanoic acid (C15:0), an odd-chain saturated free fatty acid; ~98%+ pure synthetic or plant-derived in supplement formulations.

Benefits

Cellular Energy and Mitochondrial Support

Pentadecanoic acid integrates into mitochondrial membranes and has been associated with improved mitochondrial respiratory function in cell-based assays. This may support cellular energy production, particularly in tissues with high metabolic demand such as muscle, brain, and liver.

Inflammatory Tone Modulation

C15:0 has demonstrated anti-inflammatory activity across multiple cell systems, including reduced production of pro-inflammatory cytokines. This supports its positioning as a fatty acid that may help maintain healthy inflammatory balance in aging and stressed tissues.

Cardiometabolic Marker Support

Observational studies have linked higher circulating C15:0 levels to favorable cardiometabolic profiles, including healthier triglyceride, glucose, and inflammatory markers. The data are correlational but biologically consistent with mechanistic findings in cells.

Longevity Pathway Activation

C15:0 has been shown to activate AMPK and PPAR signaling — pathways involved in cellular stress resistance, fatty acid oxidation, and longevity-associated processes. These mechanisms position the fatty acid within the broader nutraceutical landscape of metabolic-health and healthy-aging support.

Antifibrotic Activity

Cell-based work suggests C15:0 may help dampen fibrotic responses in liver and other tissues by modulating TGF-beta signaling and inflammatory cascades. The translational relevance to human metabolic-associated fatty liver disease is an active area of investigation.

Mechanism of action

1

Membrane Saturation and Integrity

As a saturated odd-chain fatty acid, C15:0 incorporates into phospholipid membranes and may stabilize membrane fluidity in ways differentiated from even-chain saturates. This structural role is hypothesized to influence membrane-protein function and cellular resilience.

2

AMPK Pathway Activation

C15:0 has been reported to activate AMP-activated protein kinase, the cellular energy sensor that promotes mitochondrial biogenesis, fatty acid oxidation, and metabolic flexibility. AMPK activation underlies many longevity-associated interventions.

3

PPAR-alpha and PPAR-delta Signaling

The fatty acid binds and modulates peroxisome proliferator-activated receptors, transcription factors that orchestrate fatty acid oxidation, lipid handling, and anti-inflammatory gene programs. This receptor activity is one proposed substrate for C15:0's metabolic effects.

4

Anti-Inflammatory Cytokine Modulation

C15:0 reduces expression and release of inflammatory cytokines including TNF-alpha and IL-6 in stressed cells. This anti-inflammatory signature has been observed across multiple cell types and disease-relevant models.

Clinical trials

1
Pentadecanoic Acid Cellular Disease Systems Screening

Cell-based screening of pentadecanoic acid across 12 primary human disease systems, comparing it head-to-head with omega-3 EPA on inflammatory, immune, fibrotic, and metabolic endpoints. (Venn-Watson et al, PLoS One)

Primary human cell-based disease models (in vitro).

C15:0 showed broader and safer clinically-relevant activities than omega-3 across the 12 systems tested, including stronger anti-inflammatory and antifibrotic profiles with fewer off-target effects. Provides mechanistic basis for promoting C15:0 as a candidate essential fatty acid distinct from omega-3 fatty acids.

2
Pentadecanoic Acid as a Candidate Essential Fatty Acid

Foundational paper proposing C15:0 as a previously unrecognized essential dietary fatty acid based on convergent evidence from cell assays, animal studies, and human observational data. (Venn-Watson, Lumpkin, Dennis, Sci Rep)

Multi-system integrated analysis: cell, animal, human observational data.

Pentadecanoic acid attenuated inflammation, anemia, dyslipidemia, and fibrosis across the systems analyzed, with proposed mitochondrial-repair mechanisms. Authors argue the convergent evidence supports essentiality status — a designation that remains under active scientific discussion.

3
Pentadecanoic Acid Essentiality — Mini-Review

Mini-review summarizing accumulating cellular, animal, and human data on pentadecanoic acid's biological roles and the ongoing debate about its candidate essentiality status. (Ciesielski et al, Biochimie)

Narrative review of literature.

The review surveys C15:0's metabolic and anti-inflammatory activity but notes the essentiality framework remains controversial and requires independent confirmation. It outlines what additional human trial evidence would be needed to formally classify C15:0 as essential.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at the studied mg-scale doses.
Mild GI upset, particularly if taken without food.
Rare reports of belching or oily aftertaste with higher doses.
Long-term safety data above 200 mg/day is limited.
No major adverse events reported in published human safety screens at studied doses.

Important Drug interactions

No major drug-drug interactions identified in published literature to date
Anticoagulants (warfarin, DOACs) — saturated fatty acids generally do not affect coagulation, but discuss with prescriber
Statins — co-supplementation is theoretically complementary for cardiometabolic support; monitor lipid panel
Diabetes medications — monitor glucose during initiation given proposed metabolic-health effects

Frequently asked questions about Pentadecanoic Acid (C15:0)

What is the recommended dosage of Pentadecanoic Acid (C15:0)?

The clinically studied dose for Pentadecanoic Acid (C15:0) is 100-200 mg/day (single capsule); taken with food. Most published cellular and observational work supports the low-mg daily dose range; long-term human RCT dose ranging is still emerging.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Pentadecanoic Acid (C15:0) used for?

Pentadecanoic Acid (C15:0) is studied for cellular energy and mitochondrial support, inflammatory tone modulation, cardiometabolic marker support. Pentadecanoic acid integrates into mitochondrial membranes and has been associated with improved mitochondrial respiratory function in cell-based assays.

Are there side effects from taking Pentadecanoic Acid (C15:0)?

Reported potential side effects may include: Generally well-tolerated at the studied mg-scale doses. Mild GI upset, particularly if taken without food. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Pentadecanoic Acid (C15:0) interact with medications?

Known drug interactions may include: No major drug-drug interactions identified in published literature to date Anticoagulants (warfarin, DOACs) — saturated fatty acids generally do not affect coagulation, but discuss with prescriber Consult a pharmacist or healthcare provider if you take prescription medications.

Is Pentadecanoic Acid (C15:0) good for longevity?

Yes, Pentadecanoic Acid (C15:0) is researched for Longevity support. C15:0 has been shown to activate AMPK and PPAR signaling — pathways involved in cellular stress resistance, fatty acid oxidation, and longevity-associated processes.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Sci Rep. 2020;10(1):8161. doi: 10.1038/s41598-020-64960-y.PubMedUsed to support: Foundational paper proposing C15:0 as a candidate essential fatty acid; integrates cellular, animal, and human data showing C15:0 attenuates inflammation, anemia, dyslipidemia, and fibrosis with mitochondrial-repair mechanisms
  2. Venn-Watson SK, Butterworth CN. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS One. 2022;17(5):e0268778. doi: 10.1371/journal.pone.0268778.PubMedUsed to support: Twelve-system cell-based head-to-head screening comparing C15:0 with EPA omega-3; C15:0 showed broader and safer clinically-relevant activities including stronger anti-inflammatory and antifibrotic profiles
  3. Ciesielski V, Legrand P, Blat S, Rioux V. New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie. 2024;227(Pt B):123-129. doi: 10.1016/j.biochi.2024.10.008.PubMedUsed to support: Recent mini-review summarizing accumulating evidence on pentadecanoic acid biology and outlining the ongoing scientific debate over essentiality status — supports evidence-density honesty in this entry